Prevention of Chemotherapy-induced Peripheral Neuropathy: A Review of Recent Findings

Overview

Journal Crit Rev Oncol Hematol

Specialty Hematology

Date 2019 Nov 30

PMID 31783290

Citations 68

Authors

Eiman Y Ibrahim

Barbara E Ehrlich

Affiliations

Soon will be listed here.

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is an adverse effect of chemotherapy that is frequently experienced by patients receiving treatment for cancer. CIPN is caused by many of the most commonly used chemotherapeutic agents, including taxanes, vinca alkaloids, and bortezomib. Pain and sensory abnormalities may persist for months, or even years after the cessation of chemotherapy. The management of CIPN is a significant challenge, as it is not possible to predict which patients will develop symptoms, the timing for the appearance of symptoms can develop anytime during the chemotherapy course, there are no early indications that warrant a reduction in the dosage to halt CIPN progression, and there are no drugs approved to prevent or alleviate CIPN. This review focuses on the etiology of CIPN and will highlight the various approaches developed for prevention and treatment. The goal is to guide studies to identify, test, and standardize approaches for managing CIPN.

Citing Articles

A novel model of paclitaxel-induced peripheral neuropathy produces a clinically relevant phenotype in mice.

Osborn L, Bishop M, Rodriguez K, Redling D, Duplechain E, Stephens K bioRxiv. 2025; .

PMID: 39990336 PMC: 11844414. DOI: 10.1101/2025.02.10.637458.

6-Hydroxyflavanone treats anxiety and chemotherapy-induced neuropathy in Sprague-Dawley rats.

Akbar S, Subhan F, Qamar R, Akbar A, Shahbaz N, Aamir M Front Pharmacol. 2025; 15:1486918.

PMID: 39744130 PMC: 11688605. DOI: 10.3389/fphar.2024.1486918.

Development of a Novel Microphysiological System for Peripheral Neurotoxicity Prediction Using Human iPSC-Derived Neurons with Morphological Deep Learning.

Han X, Matsuda N, Yamanaka M, Suzuki I Toxics. 2024; 12(11).

PMID: 39590989 PMC: 11598741. DOI: 10.3390/toxics12110809.

Neuroprotective effect of chelidonic acid through oxidative stress reduction in paclitaxel-induced peripheral neuropathy in rats.

Khairnar S, Kulkarni Y, Singh K Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39480525 DOI: 10.1007/s00210-024-03550-5.

Chinese Medicine in Colorectal Cancer Treatment: From Potential Targets and Mechanisms to Clinical Application.

Guo K, Wang Z, Su X Chin J Integr Med. 2024; .

PMID: 39331211 DOI: 10.1007/s11655-024-4115-8.

References

Dorsey S, Kleckner I, Barton D, Mustian K, OMara A, St Germain D . The National Cancer Institute Clinical Trials Planning Meeting for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy. J Natl Cancer Inst. 2019; 111(6):531-537. PMC: 7962883. DOI: 10.1093/jnci/djz011. View

Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B . Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009; 2:36. PMC: 2736171. DOI: 10.1186/1756-8722-2-36. View

Maestri A, Ceratti A, Cundari S, Zanna C, Cortesi E, Crino L . A pilot study on the effect of acetyl-L-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy. Tumori. 2005; 91(2):135-8. DOI: 10.1177/030089160509100206. View

Scripture C, Figg W, Sparreboom A . Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives. Curr Neuropharmacol. 2008; 4(2):165-72. PMC: 2430667. DOI: 10.2174/157015906776359568. View

Ciampi de Andrade D, Teixeira M, Galhardoni R, Ferreira K, Braz Mileno P, Scisci N . Pregabalin for the Prevention of Oxaliplatin-Induced Painful Neuropathy: A Randomized, Double-Blind Trial. Oncologist. 2017; 22(10):1154-e105. PMC: 5634769. DOI: 10.1634/theoncologist.2017-0235. View

Ge W, Jakobsson E . Systems Biology Understanding of the Effects of Lithium on Cancer. Front Oncol. 2019; 9:296. PMC: 6503094. DOI: 10.3389/fonc.2019.00296. View

Manasanch E, Orlowski R . Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol. 2017; 14(7):417-433. PMC: 5828026. DOI: 10.1038/nrclinonc.2016.206. View

Filosto M, Rossi G, Pelizzari A, Buzio S, Tentorio M, Broglio L . A high-dose bortezomib neuropathy with sensory ataxia and myelin involvement. J Neurol Sci. 2007; 263(1-2):40-3. DOI: 10.1016/j.jns.2007.05.023. View

Kolb N, Smith A, Singleton J, Beck S, Stoddard G, Brown S . The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling. JAMA Neurol. 2016; 73(7):860-6. PMC: 6715416. DOI: 10.1001/jamaneurol.2016.0383. View

10.

Kanat O, Ertas H, Caner B . Platinum-induced neurotoxicity: A review of possible mechanisms. World J Clin Oncol. 2017; 8(4):329-335. PMC: 5554876. DOI: 10.5306/wjco.v8.i4.329. View

11.

Broyl A, Corthals S, Jongen J, van der Holt B, Kuiper R, de Knegt Y . Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol. 2010; 11(11):1057-65. DOI: 10.1016/S1470-2045(10)70206-0. View

12.

Wadia R, Stolar M, Grens C, Ehrlich B, Chao H . The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients. Oncotarget. 2018; 9(7):7322-7331. PMC: 5800905. DOI: 10.18632/oncotarget.23467. View

13.

Hertz D, Roy S, Motsinger-Reif A, Drobish A, CLARK L, McLeod H . CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Ann Oncol. 2013; 24(6):1472-8. PMC: 3660078. DOI: 10.1093/annonc/mdt018. View

14.

Boyette-Davis J, Hou S, Abdi S, Dougherty P . An updated understanding of the mechanisms involved in chemotherapy-induced neuropathy. Pain Manag. 2018; 8(5):363-375. PMC: 6462837. DOI: 10.2217/pmt-2018-0020. View

15.

Boehmerle W, Zhang K, Sivula M, Heidrich F, Lee Y, Jordt S . Chronic exposure to paclitaxel diminishes phosphoinositide signaling by calpain-mediated neuronal calcium sensor-1 degradation. Proc Natl Acad Sci U S A. 2007; 104(26):11103-8. PMC: 1904151. DOI: 10.1073/pnas.0701546104. View

16.

Zanville N, Nudelman K, Smith D, Von Ah D, McDonald B, Champion V . Evaluating the impact of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) on perceived ability to work in breast cancer survivors during the first year post-treatment. Support Care Cancer. 2016; 24(11):4779-89. PMC: 5031751. DOI: 10.1007/s00520-016-3329-5. View

17.

Balayssac D, Ferrier J, Descoeur J, Ling B, Pezet D, Eschalier A . Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence. Expert Opin Drug Saf. 2011; 10(3):407-17. DOI: 10.1517/14740338.2011.543417. View

18.

Staff N, Grisold A, Grisold W, Windebank A . Chemotherapy-induced peripheral neuropathy: A current review. Ann Neurol. 2017; 81(6):772-781. PMC: 5656281. DOI: 10.1002/ana.24951. View

19.

Zheng H, Xiao W, Bennett G . Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy. Exp Neurol. 2011; 232(2):154-61. PMC: 3202047. DOI: 10.1016/j.expneurol.2011.08.016. View

20.

Izgu N, Gok Metin Z, Karadas C, Ozdemir L, Cetin N, Demirci U . Prevention of chemotherapy-induced peripheral neuropathy with classical massage in breast cancer patients receiving paclitaxel: An assessor-blinded randomized controlled trial. Eur J Oncol Nurs. 2019; 40:36-43. DOI: 10.1016/j.ejon.2019.03.002. View